Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinigen Raises $80 Mil. In Rare U.K. Flotation While Europe's Wellington Partners Raises $91 Mil. For New Life Sciences Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Hopes in Europe’s cash-strapped biotech sector were rekindled when specialty drug and contract services company Clinigen said it will be Britain’s first public pharma listing in five years and by investors from Europe, the U.S. and the Middle East piling into a new life sciences investment fund set up by pan-European VC firm Wellington Partners.

You may also be interested in...



Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011

Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.

e-Therapeutics Explores Network Pharmacology For Drug Discovery, Moves First Of Its Drugs Into Clinical Studies

The U.K. company e-Therapeutics outlines its novel "network pharmacology" approach for discovery R&D, its product pipeline, and collaboration plans as it moves its first product, with potential in cancer, into Phase I studies.

New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding

The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel